与常见可变免疫缺陷相关的免疫血小板缩症患者的临床和免疫学表征
Nadia Somasundaram1, Oliver Meyer2, Carmen Scheibenbogen1
1Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Institute of Medical Immunology, Augustenburger Platz 1, 13353, Berlin, Germany.
Clinical and experimental medicine
|September 5, 2023
概括
与常见的可变免疫缺陷 (CVID) 相关的免疫性血栓缺陷 (ITP) 呈现出比单独的ITP更轻微的症状和更高的缓解率. 建议对ITP患者进行CVID查,以早期检测免疫异常.
科学领域:
- 免疫学 免疫学 免疫学
- 血液学 血液学 血液学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 初级免疫性血小板缺血 (ITP) 是一种自身免疫性疾病.
- 二次性ITP可能源于诸如常见变性免疫缺陷 (CVID) 这样的潜在疾病.
- ITP是CVID患者中最常见的自身免疫并发症.
研究的目的:
- 将CVID相关ITP的临床和免疫特征与非CVIDITP进行比较.
- 为了评估疾病的严重程度,缓解率和两组患者的治疗需求.
- 确定潜在的生物标志物,以区分与CVID相关的ITP.
主要方法:
- 单中心研究比较了20名患有CVID相关ITP的患者和20名没有CVID的ITP患者.
- 临床评估包括世卫组织出血量表和治疗史.
- 免疫学特征,包括可溶性互白素-2受体 (sIL-2R,CD25) 水平和免疫缺陷查.
主要成果:
- 与CVID相关的ITP患者初始出血严重程度较高,但在治疗较少的情况下实现了更高的缓解率.
- 与ITP患者相比,与CVID相关的ITP患者需要二线药物治疗的患者较少.
- 与CVID相关的ITP中,可溶性互白素-2受体 (sIL-2R,CD25) 水平显著更高,AUC为0.92用于分类.
- 免疫学异常,包括免疫球蛋白水平降低和淋巴细胞衰减,在没有免疫缺陷病史的ITP患者中发现了很大一部分.
结论:
- 与CVID相关的ITP中的血小板缺血遵循较温和的过程.
- 升高的sIL-2R (CD25) 可能作为CVID相关ITP的生物标志物.
- 在ITP患者中进行CVID和其他免疫缺陷的常规查是有必要的,以早期检测潜在的免疫异常.
相关概念视频
01:25Immunodeficiency Diseases
973
Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
There are three main causes of immunodeficiency...
973
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
14
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
14
01:24Disorders of Hemostasis
989
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
989
01:27Myocarditis II: Clinical Features and Diagnostic Tests
12
Myocarditis is an inflammation of the heart muscle. The symptoms vary widely, encompassing asymptomatic presentations to severe, acute manifestations.Clinical PresentationAsymptomatic cases: In some instances, myocarditis may be asymptomatic, with the infection resolving without intervention. These cases often go undetected unless discovered incidentally through diagnostic imaging or tests conducted for other reasons.General Early Symptoms: Early symptoms of myocarditis are non-specific and can...
12
02:45Blood Transfusion and Agglutination
10.9K
Blood transfusion is a therapeutic measure to restore the blood volume after extensive blood loss due to an accident or a medical procedure. Blood transfusion involves drawing a certain amount of blood from a suitable donor and infusing it into the recipient.
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
History
The history of blood transfusion dates back to the 17th century, when early attempts were made in animals. In 1818 James Blundell, a British doctor, performed the first successful human blood transfusion. Later in 1900, Karl...
10.9K
01:22Development of Immunocompetence
342
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
342